keyword
MENU ▼
Read by QxMD icon Read
search

PLA2R

keyword
https://www.readbyqxmd.com/read/27921164/m-type-phospholipase-a2-receptor-pla2r-glomerular-staining-in-pediatric-idiopathic-membranous-nephropathy
#1
Shoichiro Kanda, Shigeru Horita, Takeshi Yanagihara, Akira Shimizu, Motoshi Hattori
BACKGROUND: Identifying M-type phospholipase A2 receptor (PLA2R) is a landmark breakthrough for understanding adult idiopathic membranous nephropathy (iMN). However, potential roles for PLA2R in pediatric iMN have not been well investigated. METHODS: A total of 34 pediatric iMN patients who underwent kidney biopsy between 1972 and 2015 were enrolled in this study. The study cohort consisted of 15 children aged from 3 to 9 years and 19 aged from 10 to 15 years...
December 5, 2016: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/27890680/the-putative-role-of-maldi-msi-in-the-study-of-membranous-nephropathy
#2
Andrew Smith, Vincenzo L'Imperio, Elena Ajello, Franco Ferrario, Niccolò Mosele, Martina Stella, Manuel Galli, Clizia Chinello, Federico Pieruzzi, Goce Spasovski, Fabio Pagni, Fulvio Magni
Membranous Nephropathy (MN) is an immunocomplex mediated renal disease that represents the leading cause of nephrotic syndrome in adults and is one of the most frequent glomerulopathies worldwide. This glomerular disease can manifest as primary (idiopathic) or secondary and this distinction is crucial when choosing the most appropriate management of patients. In secondary cases, the best strategy consists in treating the underlying disease whereas in primary forms, the possible identification of confirmatory markers of the idiopathic etiology underlining the process is requested by clinicians...
November 23, 2016: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/27876629/improvement-of-idiopathic-membranous-nephropathydiagnosis-with-ultrasensitive-quantitative-detection-of-anti-phospholipase-a2-receptor
#3
Biao Huang, Liang Wang, Ya-Nan Cao, Yi Zhang, Jue Zhang, Hualong Xiao, Qiuhua Zhang, Weidong Wang, Zhuxing Sun, Yu Chen, Huiming Sheng, Zhigang Hu
The work focused on development of a sensitive, quantitative assay for serum PLA2R-IgG with wide dynamic working range, as an aid to differential diagnosis of IMN and to exclude secondary Membranous Nephropathy with slight elevation of anti-PLA2R-IgG from IMN.
November 19, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27876003/pla2r-antibodies-and-pla2r-glomerular-deposits-in-psoriasis-patients-with-membranous-nephropathy
#4
Yong-Chun Ge, Bo Jin, Cai-Hong Zeng, Ming-Chao Zhang, Da-Cheng Chen, Ru Yin, Wei-Bo Le
BACKGROUND: The association between psoriasis and membranous nephropathy (MN) remains largely unclear. We examined the prevalence of serum PLA2R antibody and characterized the expression of PLA2R and THSD7A in glomeruli in patients with MN and psoriasis. METHODS: A total of 24 patients with MN without evidence of a secondary cause except psoriasis were enrolled. The clinical and pathological features were retrospectively analyzed. Serum anti-PLA2R antibody was measured using IFA Mosaic...
November 22, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27852637/mhc-class-ii-risk-alleles-and-amino-acid-residues-in-idiopathic-membranous-nephropathy
#5
Zhao Cui, Li-Jun Xie, Fang-Jin Chen, Zhi-Yong Pei, Li-Jie Zhang, Zhen Qu, Jing Huang, Qiu-Hua Gu, Yi-Miao Zhang, Xin Wang, Fang Wang, Li-Qiang Meng, Gang Liu, Xu-Jie Zhou, Li Zhu, Ji-Cheng Lv, Fan Liu, Hong Zhang, Yun-Hua Liao, Lu-Hua Lai, Pierre Ronco, Ming-Hui Zhao
Epitopes of phospholipase A2 receptor (PLA2R), the target antigen in idiopathic membranous nephropathy (iMN), must be presented by the HLA-encoded MHC class II molecules to stimulate autoantibody production. A genome-wide association study identified risk alleles at HLA and PLA2R loci, with the top variant rs2187668 within HLA-DQA1 showing a risk effect greater than that of the top variant rs4664308 within PLA2R1. How the HLA risk alleles affect epitope presentation by MHC class II molecules in iMN is unknown...
November 16, 2016: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/27807329/-role-of-m-type-phospholipase-a2-receptor-and-its-antibody-in-hepatitis-b-virus-associated-membranous-nephropathy
#6
Xiangqing Xu, Xuejing Zhu, Shuguang Yuan, Wenling Jiang, Yuncheng Xia, Hong Liu, Jun Li, Lin Sun, Youming Peng, Fuyou Liu
To examine levels of M-type phospholipase A2 receptor (PLA2R) and its antibody in the patients with hepatitis B virus-associated membranous nephropathy (HBV-MN), and to explore the correlation of PLA2R with laboratory parameters and pathological characteristics.
 Methods: A total of 49 adult patients with biopsy-proved HBV-MN were enrolled in this study. Levels of anti-PLA2R antibody in serum and PLA2R in renal tissue were detected. Patients were assigned into two groups: a positive PLA2R group and a negative PLA2R group...
October 28, 2016: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/27777266/a-proposal-for-a-serology-based-approach-to-membranous-nephropathy
#7
An S De Vriese, Richard J Glassock, Karl A Nath, Sanjeev Sethi, Fernando C Fervenza
Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by autoantibodies against the recently discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A). Assays for quantitative assessment of anti-PLA2R antibodies are commercially available, but a semiquantitative test to detect anti-THSD7A antibodies has been only recently developed. The presence or absence of anti-PLA2R and anti-THSD7A antibodies adds important information to clinical and immunopathologic data in discriminating between primary and secondary MN...
October 24, 2016: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/27692613/-membranous-nephropathy-diagnosis-new-insights-in-pathophysiology-and-therapeutic-approach
#8
K Dahan
Membranous nephropathy (MN) accounts for about 20% of cases of nephrotic syndrome in the adult. Thickening of glomerular capillary walls results from subepithelial formation of immune deposits containing IgG and the membrane attack complex of complement, which is the major mediator of proteinuria, and antigens. Idiopathic forms of MN (IMN) represent 70 to 80% of all cases. A major breakthrough was the identification of the podocyte antigen PLA2R as the target of circulating antibodies in about 70% of IMN, which confirmed that the disease was auto-immune in nature...
May 25, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27646575/membranous-nephropathy-in-the-kidney-allograft
#9
REVIEW
Edward J Filippone, John L Farber
Membranous nephropathy (MN) may occur in a kidney transplant as recurrence of the original disease (rMN) or as a de novo MN (dnMN). rMN often occurs early, within the first year, and often in a mild or subclinical fashion. Recurrence cannot be predicted by clinical features at the time of transplantation. The natural history is increasing proteinuria over time, with less chance for spontaneous remission compared to primary MN (pMN). Antiphospholipase A2 receptor (PLA2R) antibodies should be evaluated in all patients with pMN at the time of transplantation and serially...
November 2016: Clinical Transplantation
https://www.readbyqxmd.com/read/27634909/biomarkers-to-detect-membranous-nephropathy-in-chinese-patients
#10
Li Lin, Wei Ming Wang, Xiao Xia Pan, Jing Xu, Chen Ni Gao, Wen Zhang, Hong Ren, Jing Yuan Xie, Pin Yan Shen, Yao Wen Xu, Li Yan Ni, Nan Chen
Anti-M-type phospholipase A2 receptor (anti-PLA2R) is a widely accepted biomarker for clinical idiopathic membranous neurophathy (IMN). However, its ability to differentiate between IMN and secondary MN (SMN) is controversial. The objective of this study was to assess clinical MN biomarkers in blood, tissue and urine samples from Chinese patients. In total, 195 MN patients and 70 patients with other glomerular diseases were prospectively enrolled in the study. Participants were followed up for average of 17 months (range 3-39 months)...
September 13, 2016: Oncotarget
https://www.readbyqxmd.com/read/27631233/hla-dr-and-not-pla2r-is-expressed-on-the-podocytes-in-kidney-allografts-in-de-novo-membranous-nephropathy
#11
Jiqiu Wen, Kenan Xie, Mingchao Zhang, Jinsong Chen, Jiong Zhang, Dongrui Cheng, Xue Li, Shuming Ji, Zhihong Liu
Idiopathic membranous nephropathy (IMN) is known to be associated with antibodies acting on the M-type phospholipase A2 receptor (PLA2R) of the podocyte. However, the mechanism underlying de novo membranous nephropathy (dn MN) posttransplantation remains unclear. In this study, we aimed to elucidate the mechanism underlying dn MN.We selected 8 cases with dn MN and compared them to 20 IMN cases. Fifteen cases of stable grafts were selected as controls.Several differences between the dn MN group and the IMN group were detected...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27624606/clinicopathological-features-of-idiopathic-membranous-nephropathy-combined-with-iga-nephropathy-a-retrospective-analysis-of-9-cases
#12
Ruimin Hu, Guolan Xing, Huijuan Wu, Zhigang Zhang
BACKGROUND: The concomitant presence of idiopathic membranous nephropathy and IgA nephropathy is rare. Here, we report 9 cases of phospholipase-A2-receptor (PLA2R) positive idiopathic membranous nephritis combined with IgA nephropathy, while reviewing publications regarding the pathological characteristics of this glomerolonephritis complication. CASE PRESENTATION: Nine cases of renal biopsy tissues were retrospectively reviewed, including the clinicopathological features, the results of the immunofluorescence assays, and the electron microscopic examination...
September 13, 2016: Diagnostic Pathology
https://www.readbyqxmd.com/read/27536673/management-of-membranous-nephropathy-in-western-countries
#13
REVIEW
Talal Alfaadhel, Daniel Cattran
BACKGROUND: Idiopathic membranous nephropathy (IMN) is a common cause of nephrotic syndrome (NS) in adults in Western countries. In 2012, the KDIGO (Kidney Disease: Improving Global Outcomes) working group published guidelines for the management of glomerulonephritis, thus providing a template for the treatment of this condition. While being aware of the impact of the clinicians' acumen and that patients may choose a different therapeutic option due to the risks of specific drugs and also of the evolving guidelines, this review details our approach to the management of patients with IMN in a Western center (Toronto)...
September 2015: Kidney Diseases
https://www.readbyqxmd.com/read/27536672/management-of-membranous-nephropathy-in-asia
#14
REVIEW
Jing Xu, Xiaofan Hu, Jingyuan Xie, Nan Chen
BACKGROUND: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome (NS) in adults, accounting for about 20.0% of all NS cases. With an increasing prevalence, especially in the elderly, it has received great attention in Asia. SUMMARY: Recently, the prevalence of idiopathic MN (IMN) has significantly increased among the elderly people in Asia and other places in the world. Although the exact mechanism of IMN remains unveiled, the identification of new antigens such as PLA2R and THSD7A has greatly enhanced our understanding of its pathogenesis...
September 2015: Kidney Diseases
https://www.readbyqxmd.com/read/27535699/pharmacological-treatment-of-primary-membranous-nephropathy-in-2016
#15
Anne-Els van de Logt, Julia M Hofstra, Jack F Wetzels
INTRODUCTION: Therapy in patients with primary membranous nephropathy is debated. The discovery of anti-PLA2R antibodies provides opportunities for new treatment strategies. AREAS COVERED: The PubMed database and Cochrane library were searched for full-text articles published in English before March 2016. The search terms included 'Glomerulonephritis, Membranous' [MESH], 'membranous glomerulonephritis' [tiab] and, 'idiopathic membranous nephropathy' [tiab] and 'membranous nephropathy' [tiab], in combination with 'Therapeutics' [MESH], 'therapeutic*'[tiab], 'immunosuppression' [MESH] and 'immunosuppression' [tiab]...
September 16, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27512297/prevalence-of-serum-anti-m-type-phospholipase-a2-receptor-antibody-in-primary-membranous-nephropathy-a-single-center-experience
#16
N Gopalakrishnan, P Abeesh, T Dineshkumar, S Murugananth, R Sakthirajan, G Srinivasa Raman, J Dhanapriya, T Balasubramaniyan, Md Haris
We conducted a prospective study to assess utility of detection of antibodies to phospholipase A2receptor (PLA2R) in the serum of patients with membranous nephropathy. Seventy five patients with biopsy proven membranous nephropathy admitted between January 2011 and September 2014 were studied. Serum anti- PLA2R was tested by indirect immunofluorescence. The test was positive in 45 out of 60 patients with primary membranous nephropathy (PMN) and in none of the 15 patients with secondary membranous nephropathy, with a sensitivity of 75% and specificity of 100% for PMN...
July 2016: Indian Journal of Nephrology
https://www.readbyqxmd.com/read/27390744/phospholipase-a2-receptor-positive-idiopathic-membranous-glomerulonephritis-with-onset-at-95-years-case-report
#17
Keiichi Kubota, Junichi Hoshino, Toshiharu Ueno, Koki Mise, Ryo Hazue, Akinari Sekine, Junko Yabuuchi, Masayuki Yamanouchi, Tatsuya Suwabe, Koichi Kikuchi, Keiichi Sumida, Noriko Hayami, Naoki Sawa, Kenmei Takaichi, Takeshi Fujii, Kenichi Ohashi, Shinichi Akiyama, Shoichi Maruyama, Yoshifumi Ubara
A 95-year-old woman was admitted to our hospital for evaluation of bilateral lower-limb edema persisting for 3 months. Serum creatinine was 1.55 mg/dl, and urinary protein excretion was 9.1 g/day. Renal biopsy revealed stage 1 membranous glomerulonephritis (MGN) with immunoglobulin G4-dominant staining. This patient did not have any underlying disease such as infection with hepatitis B or C virus or malignancy, and anti-phospholipase A2 receptor (PLA2R) antibody was detected in the serum. Accordingly, idiopathic MGN was diagnosed...
May 2016: Case Reports in Nephrology and Dialysis
https://www.readbyqxmd.com/read/27387472/low-dose-rituximab-is-poorly-effective-in-patients-with-primary-membranous-nephropathy
#18
Gabriella Moroni, Federica Depetri, Lucia Del Vecchio, Beniamina Gallelli, Francesca Raffiotta, Elisa Giglio, Francesca Brunini, Marco D'Amico, Selena Longhi, Antonella Radice, Piergiorgio Messa, Renato Alberto Sinico
BACKGROUND: The optimal dosing and the efficacy of rituximab for primary membranous nephropathy (PMN) has not been established. This multicentric prospective study evaluates the efficacy and safety of low-dose rituximab (RTX) therapy in patients with PMN in clinical practice. METHODS: Thirty-four consecutive patients with PMN and nephrotic syndrome were included and received RTX (375 mg/m(2)) once (18 patients) or twice (16 patients). RTX was the first-line therapy for 19 (56%) and the second line for 15 (44%) patients...
July 6, 2016: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/27355365/anti-phospholipase-a2-receptor-pla2r-antibody-and-glomerular-pla2r-expression-in-japanese-patients-with-membranous-nephropathy
#19
Kei Hihara, Masayuki Iyoda, Shohei Tachibana, Ken Iseri, Tomohiro Saito, Yasutaka Yamamoto, Taihei Suzuki, Yukihiro Wada, Kei Matsumoto, Takanori Shibata
The phospholipase A2 receptor (PLA2R) is the major target antigen (Ag) in idiopathic membranous nephropathy (IMN). Recently, several types of immunoassay systems for anti-PLA2R antibody (Ab) have been developed. However, the correlation of serum anti-PLA2R Abs and glomerular expression of PLA2R Ag, and their association with clinicopathological characteristics have yet to be proven in Japanese patients. We examined serum anti-PLA2R Abs by both ELISA and cell-based indirect immunofluorescence assay (CIIFA), and glomerular PLA2R expression by immunofluorescence (IF) in 59 biopsy-proven MN patients including IMN (n = 38) and secondary MN (SMN) (n = 21)...
2016: PloS One
https://www.readbyqxmd.com/read/27352623/rituximab-for-severe-membranous-nephropathy-a-6-month-trial-with-extended-follow-up
#20
Karine Dahan, Hanna Debiec, Emmanuelle Plaisier, Marine Cachanado, Alexandra Rousseau, Laura Wakselman, Pierre-Antoine Michel, Fabrice Mihout, Bertrand Dussol, Marie Matignon, Christiane Mousson, Tabassome Simon, Pierre Ronco
Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m(2) intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median times to last follow-up were 17.0 (interquartile range, 12...
June 27, 2016: Journal of the American Society of Nephrology: JASN
keyword
keyword
41081
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"